04:58pm Sunday 17 December 2017

Targeting the strain of bacteria that causes ulcers may help prevent stomach cancer

About two-thirds of us have H. pylori in our bodies, but in most cases we experience no discomfort or other symptoms. However, it can be eradicated with a simple short course of antibiotics, often used with another medicine that suppresses the production of gastric acid. To determine whether eliminating H. pylori might reduce the incidence of gastric cancer, researchers analysed all published randomized controlled trials comparing at least one week of H. pylori therapy, with placebo or no treatment, in otherwise healthy and asymptomatic H. pylori-positive adults. The review included only trials that followed participants for at least two years and that had at least two participants who developed gastric cancer.

Six trials with a total of nearly 6500 participants met the researchers’ criteria. One study was conducted in Colombia and the remainder were conducted in Asian countries, with four in China and one in Japan where stomach cancer is more common. The studies mainly used a combination of antibiotics with medicines from a class of drugs that suppress gastric acid production (Proton Pump Inhibitors). An analysis of the studies’ results revealed that combining antibiotics with gastric acid suppressor therapy given for between 1 and 2 weeks prevented the development of gastric cancer compared with placebo or no treatment: in the studies, 51/3294 (1.6%) of the people given H. pylori treatment developed gastric cancer compared with 76/3203 (2.4%) given no treatment or a placebo. However, the number of deaths from gastric cancer in the trials was low, and there was insufficient evidence to be certain whether eradication improved survival.

“The findings of this systematic review and meta-analysis add to the increasing evidence that eradicating H. pylori in the general population has the potential to prevent gastric cancer. International guidelines for the management of H. pylori infection may change as a result,” said co-author Paul Moayyedi, of McMaster University, in Canada. “More research is needed on the extent of this effect and on any potential harms of H. pylori treatment before it can be advocated as a means of preventing gastric cancer.“

“The review highlights the need for further trials in different populations to provide more evidence, and these should report both the benefits and harms of such an approach,” said lead author Alex Ford, of St. James’s University Hospital, and Leeds University in the UK.
Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com. (Would you prefer to access this paper instantly? You can register for a login to our Press Room here.)

Full citation: Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD005583. DOI: 10.1002/14651858.CD005583.pub2
URL: http://doi.wiley.com/10.1002/14651858.CD005583.pub2

For further information: Please contact Susan Emigh, Director, Public Relations, Faculty of Health Sciences, McMaster University, Tel: 905-525-9140, ext. 22555, Cell: 905-518-3642, emighs@mcmaster.ca, or Jo Anthony, Senior Media and Communications Officer, Cochrane at M +44(0) 7582 726 634 or janthony@cochrane.org, pressoffice@cochrane.org.

About Cochrane
Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health. Cochrane produces reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. These are called systematic reviews. Cochrane is a not-for profit organisation with collaborators from more than 120 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Our work is recognised as representing an international gold standard for high quality, trusted information. Find out more at http://cochrane.org Follow us on twitter @cochranecollab

About Wiley
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice, and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company’s website can be accessed at http://www.wiley.com.

Media contacts:
Wiley Evelyn Martinez (US): +1 201 748 6358
sciencenewsroom@wiley.com
Cochrane Library Cochrane Press Office: Jo Anthony (UK): +44 (0) 7582 726 634


Share on:
or:

MORE FROM Cancers

Health news